Director, Genitourinary Oncology
Cleveland Clinic Foundation
Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at Taussig cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic Foundation.
Dr. Gupta obtained her MD at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. She completed Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship at Thomas Jefferson University. Dr. Gupta was a faculty at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics from 2011 until 2015. From 2015 until 2019, she was Associate Professor and Lead for the Solid Tumor Phase 1 Program at Masonic Cancer Center, University of Minnesota. Dr. Gupta serves on the ASCO Annual Scientific Committee for Genitourinary Cancers and SITC Anti-PD-1/PD-L1 Resistance Task Force. She is on the panel of the SITC Cancer Immunotherapy Guidelines and the International Bladder Cancer Groups core committee and Society of International Urology Innovators.
Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Dr. has leadership roles in NCI trials and is Chair of Alliance MAINCAV trial of maintenance cabozantinib and avelumab in metastatic urothelial cancer. She is Principal Investigator of 2021 DoD Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and Co-PI of DoD Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is the Co-Chair of the Hoosier Cancer Research Network GU Working Group and Co-Chair of the Case Comprehensive Cancer Center PRMC committee.
Dr. Gupta is active in several professional organizations including ASCO, AUA, SUO, BCAN, ESMO, PCF and SITC.
Disclosure information not submitted.
Friday, April 28, 2023
8:45 AM – 9:00 AM CST
Sunday, April 30, 2023
4:30 PM – 4:50 PM CST